Unknown

Dataset Information

0

Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer.


ABSTRACT: This study aimed to examine the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) and other clinicopathological features in HER2+ MBC patients who received first-line anti-HER2 therapy. A total of 129 patients were assigned to NLR-low and NLR-high groups based on a cutoff value of 3.0 at baseline. Peripheral blood lymphocyte subsets and gene mutations in circulating tumor DNA were analyzed by flow cytometry and Next-generation sequencing, respectively. Survival was evaluated by the Kaplan-Meier method and Cox regression analysis. Of the 129 patients, 77 and 52 were assigned to the NLR-low (≤3) and NLR-high (>3) groups, respectively. Compared with NLR-high patients, the NLR-low patients had significantly longer median progression-free survival (PFS) (11.7 vs. 7.7 months) (p = 0.001, HR = 2.703 95% CI 1.543-4.736 and overall survival (OS) (37.4 vs. 28.7 months) (p = 0.044, HR = 2.254 95% CI 1.024-4.924). Furthermore, this association was independent of metastatic sites or estrogen receptor status. Peripheral blood CD3+ (p = 0.034) and CD4+ (p = 0.010) T cell numbers were significantly higher in the NLR-low group than the NLR-high group. The mutational profile of MBC was generally similar between the two groups. Baseline NLR was a prognostic factor of PFS and OS for patients with HER2+ MBC in the first-line setting. These results may facilitate the selection of patients who will benefit most from anti-HER2 treatment.

SUBMITTER: Shao B 

PROVIDER: S-EPMC9498194 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer.

Shao Bin B   Liu Xiaoran X   Li Huiping H   Song Guohong G   Di Lijun L   Jiang Hanfang H   Yan Ying Y   Zhang Ruyan R   Ran Ran R   Zhang Jiayang J   Liu Yaxin Y   Wang Huan H   Wang Jing J  

Current oncology (Toronto, Ont.) 20220825 9


This study aimed to examine the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) and other clinicopathological features in HER2+ MBC patients who received first-line anti-HER2 therapy. A total of 129 patients were assigned to NLR-low and NLR-high groups based on a cutoff value of 3.0 at baseline. Peripheral blood lymphocyte subsets and gene mutations in circulating tumor DNA were analyzed by flow cytometry and Next-generation sequencing, respectively. Survival was evaluated by the Ka  ...[more]

Similar Datasets

| S-EPMC10785455 | biostudies-literature
| S-EPMC9801394 | biostudies-literature
| S-EPMC6543004 | biostudies-literature
| S-EPMC7816171 | biostudies-literature
| S-EPMC9893782 | biostudies-literature
| S-EPMC5690700 | biostudies-literature
| S-EPMC7317009 | biostudies-literature
| S-EPMC7339475 | biostudies-literature
| S-EPMC11568322 | biostudies-literature
| S-EPMC5895303 | biostudies-literature